Abstract
Over a 9-year period 37 consecutive adults with primary refractory (n = 13) or first relapse of ALL (n = 24) received an intensive salvage chemotherapy regimen with the final intention of undergoing stem cell transplantation (SCT). Twenty-nine patients who achieved complete remission (CR) were assigned to receive autologous SCT (autoSCT) or allogeneic SCT (alloSCT) based on age and availability of a histocompatible sibling. Of the 19 patients assigned to autoSCT, 10 did not reach the transplant due to early relapse (n = 9) or fungal infection (n = 1), and nine were transplanted a median of 2.5 months (1–8) from CR, eight with an immunologically purged graft. One patient died early from ARDS and eight relapsed 2–30 months post-SCT. Three of the 10 patients assigned to alloSCT relapsed early, but all 10 received the assigned transplant a median of 2.5 months (1–7) from CR. Four died from transplant-related complications 0.7–12 months post- SCT, and six are alive and disease-free 9.7–92.6 months after the procedure. In an intention-to-treat analysis, the mean overall survival from CR for those assigned to autoSCT and alloSCT are 11.3 months (0.5–34.3) and 60.1 (2.3–98.3), respectively (log-rank, P < 0.01). only 65% of patients who reached cr and 51% of the initial 37 cases underwent the intended sct. we conclude that few adults with refractory or relapsed all actually reach sct in cr even when the protocol used is designed for this purpose. autosct appears to offer little benefit in this setting, and an allosct from a related or unrelated donor should be rapidly pursued after achieving cr.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Martino, R., Bellido, M., Brunet, S. et al. Allogeneic or autologous stem cell transplantation following salvage chemotherapy for adults with refractory or relapsed acute lymphoblastic leukemia. Bone Marrow Transplant 21, 1023–1027 (1998). https://doi.org/10.1038/sj.bmt.1701221
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1701221
Keywords
This article is cited by
-
Salvage therapy for acute chemorefractory leukemia by allogeneic stem cell transplantation: the Korean experience
Annals of Hematology (2017)
-
The Role of Allogeneic Hematopoietic Stem Cell Transplantation in the Therapy of Patients with Acute Lymphoblastic Leukemia
Current Hematologic Malignancy Reports (2012)
-
Allogeneic SCT in refractory or relapsed adult ALL is effective without prior reinduction chemotherapy
Bone Marrow Transplantation (2008)
-
Fludarabine, cytarabine, and mitoxantrone (FLAM) for the treatment of relapsed and refractory adult acute lymphoblastic leukemia. A phase study by the Polish Adult Leukemia Group (PALG)
Annals of Hematology (2006)
-
FLAG-IDA in the treatment of refractory/relapsed adult acute lymphoblastic leukemia
Annals of Hematology (2005)